Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time.

Sandmann FG, Franken MG, Steenhoek A, Koopmanschap MA.

Health Policy. 2013 Oct;112(3):285-96. doi: 10.1016/j.healthpol.2013.03.006. Epub 2013 Apr 28.

PMID:
23628483
2.

Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision making.

Franken M, Nilsson F, Sandmann F, de Boer A, Koopmanschap M.

Pharmacoeconomics. 2013 Sep;31(9):781-97. doi: 10.1007/s40273-013-0074-1.

PMID:
23839699
3.

Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.

Hoomans T, Severens JL, van der Roer N, Delwel GO.

Pharmacoeconomics. 2012 Mar;30(3):219-27. doi: 10.2165/11539850-000000000-00000.

PMID:
22074610
4.

The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.

Yong JH, Beca J, Hoch JS.

Pharmacoeconomics. 2013 Mar;31(3):229-36. doi: 10.1007/s40273-012-0022-5.

PMID:
23322588
5.

[Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].

Hoomans T, van der Roer N, Severens JL, Delwel GO.

Ned Tijdschr Geneeskd. 2010;154:A958. Dutch.

PMID:
20699045
6.

The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.

Rocchi A, Menon D, Verma S, Miller E.

Value Health. 2008 Jul-Aug;11(4):771-83. doi: 10.1111/j.1524-4733.2007.00298.x. Epub 2007 Dec 18.

7.

Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously?

Franken M, Koopmanschap M, Steenhoek A.

Z Evid Fortbild Qual Gesundhwes. 2014;108(7):383-9. doi: 10.1016/j.zefq.2014.06.016. Epub 2014 Aug 12.

PMID:
25444296
8.

Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.

Majer IM, Gelderblom H, van den Hout WB, Gray E, Verheggen BG.

J Med Econ. 2013 Sep;16(9):1106-19. doi: 10.3111/13696998.2013.819357. Epub 2013 Jul 19.

PMID:
23808902
9.

Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests.

Cleemput I, van Wilder P, Huybrechts M, Vrijens F.

Value Health. 2009 Jun;12(4):441-9. doi: 10.1111/j.1524-4733.2008.00469.x. Epub 2008 Nov 11.

10.

Including adverse drug events in economic evaluations of anti-tumour necrosis factor-╬▒ drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.

Heather EM, Payne K, Harrison M, Symmons DP.

Pharmacoeconomics. 2014 Feb;32(2):109-34. doi: 10.1007/s40273-013-0120-z. Review.

PMID:
24338344
11.

Evidence-based health care policy in reimbursement decisions: lessons from a series of six equivocal case-studies.

Van Herck P, Annemans L, Sermeus W, Ramaekers D.

PLoS One. 2013 Oct 30;8(10):e78662. doi: 10.1371/journal.pone.0078662. eCollection 2013.

12.

Drug reimbursement decision-making in Thailand, China, and South Korea.

Ngorsuraches S, Meng W, Kim BY, Kulsomboon V.

Value Health. 2012 Jan-Feb;15(1 Suppl):S120-5. doi: 10.1016/j.jval.2011.11.002.

13.

A synthesis of drug reimbursement decision-making processes in organisation for economic co-operation and development countries.

Barnieh L, Manns B, Harris A, Blom M, Donaldson C, Klarenbach S, Husereau D, Lorenzetti D, Clement F.

Value Health. 2014 Jan-Feb;17(1):98-108. doi: 10.1016/j.jval.2013.10.008.

14.
15.

[Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].

F├╝hrlinger S.

Wien Med Wochenschr. 2006 Dec;156(23-24):612-8. German.

PMID:
17211765
16.

Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?

Franken MG, Gaultney JG, Blommestein HM, Huijgens PC, Sonneveld P, Redekop WK, Uyl-de Groot CA.

Value Health. 2014 Mar;17(2):245-53. doi: 10.1016/j.jval.2013.12.009.

17.

Similarities and differences between five European drug reimbursement systems.

Franken M, le Polain M, Cleemput I, Koopmanschap M.

Int J Technol Assess Health Care. 2012 Oct;28(4):349-57. doi: 10.1017/S0266462312000530. Epub 2012 Sep 19.

PMID:
22989410
18.

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.

Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, Garside R, Anderson R.

Health Technol Assess. 2012;16(42):iii-iv, 1-277. doi: 10.3310/hta16420. Review.

19.

[Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget].

Delwel GO, Sprenger MJ.

Ned Tijdschr Geneeskd. 2002 Jun 8;146(23):1068-71. Dutch.

PMID:
12085554
20.

Methods for the comparative evaluation of pharmaceuticals.

Zentner A, Velasco-Garrido M, Busse R.

GMS Health Technol Assess. 2005 Nov 15;1:Doc09.

Supplemental Content

Support Center